30+ Civil Society Orgs to USTR: Stop Threatening to Block Colombia’s OECD Accession over Pharma/Biotech Lobby Interests

FOR IMMEDIATE RELEASE March 20, 2018 kim.treanor@keionline.org (202)-332-2670 A broad international coalition of over 30 human rights organizations, including some across the United States and Latin America, have come together to ensure that providing access to health care doesn’t come… Continue Reading

Coalition calls on US and Korea Trade Negotiators to prioritize public health over pharma corporations in trade negotiations

FOR IMMEDIATE RELEASE March 12, 2018 kim.treanor@keionline.org (202)-332-2670 A coalition of 16 advocacy organizations in the United States and Korea asked trade negotiators in the U.S. and Korea to reject the demands of the pharmaceutical industry, protect human rights, and… Continue Reading

PhRMA and BIO request EU be added to USTR Watch List over review of incentives

PhRMA and BIO have both requested that the US Trade Representative place the European Union on its watch list in the 2018 Special 301 Report. The Special 301 Report is a yearly review by the US Trade Representative of the… Continue Reading

NGOs and patient groups call upon Chilean President, Minister of Health to issue a compulsory license for cancer and Hepatitis drugs

FOR IMMEDIATE RELEASE Contact: Kim Treanor kim.treanor@keionline.org; 202-332-2670 Patient groups, civil society and concerned individuals from Chile and around the world call upon President Michelle Bachelet Jeria and Dr. Carmen Castillo Taucher, Minister of Health, to issue a compulsory license… Continue Reading

Following KEI request for investigation, Cold Spring Harbor Labs says 7 patents require correction to disclose federal funding


  • After KEI filed a complaint with the NIH, Cold Spring Harbor Laboratory (CSHL) corrected a failure to disclose funding of at least 7 patented inventions, including one patent for the drug Sprinraza.
  • Since 2012, when federal funding was relevant to an invention, CSHL failed to make a disclosure on a filed patent more than half the time.

Continue Reading

2017: Nanobernetics proposed exclusive license for NIH patents on Apparatus for Microarray Binding Sensors

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) The attached file (copy here) is the KEI questions and initial comments on the Prospective Grant of an Exclusive Patent License: Apparatus for Microarray Binding Sensors Having… Continue Reading

US Federal rights in patents on Probuphine, to treat opioid addiction

Probuphine is an expensive medication used to treat opioid dependence by providing maintenance treatment and lessening withdrawal symptoms. The U.S. federal government also has considerable leverage over the pricing of this product, because of the federal funding of the the research that lead to the sole Orange Book patent on the product, and phase 3 trials that were used the register the product.

Continue Reading